Company intelligence / Profile preview

PentaBase

Ownership: Private
Employees: ~45
Development stage: Commercial

Overview

PentaBase has developed proprietary technologies such as INA® and EpiDirect®, enabling highly sensitive and specific PCR-based assays for genetic biomarker detection in oncology and infectious diseases. Their products are used globally in both research and clinical settings. The company’s assays have demonstrated robust performance in routine diagnostics at major hospitals.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Synthetic oligonucleotidePCR assayDiagnostic assay
Industry: Molecular Diagnostics

Drug pipeline

3 assets

PlentiPlex MYD88

Commercial

Indications: Waldenström Lymphoma

2 more assets in the full pipeline.

Request access →

Partnerships

Statens Serum Institut (Denmark)Beijing Institute of Genomics (China)several foreign companies/universitiesHiSS Diagnostics distribution partnership

Beyond the preview

Go deeper on PentaBase.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PentaBase.

Explore the full profile